Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
300 | 300 | 14,463,687 | 1,662 | Compositions and methods are provided for genome modification of a target sequence in the genome of a plant or plant cell. The methods and compositions employ a guide RNA/Cas endonuclease system to provide an effective system for modifying or altering target sites within the genome of a plant, plant cell or seed. Also ... | 1. A method for selecting a plant comprising an altered target site in its plant genome, the method comprising:
a) obtaining a first plant comprising at least one Cas endonuclease capable of introducing a double strand break at a target site in the plant genome; b) obtaining a second plant comprising a guide RNA that i... | Compositions and methods are provided for genome modification of a target sequence in the genome of a plant or plant cell. The methods and compositions employ a guide RNA/Cas endonuclease system to provide an effective system for modifying or altering target sites within the genome of a plant, plant cell or seed. Also ... | 1,600 |
301 | 301 | 14,412,189 | 1,619 | The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a ... | 1-15. (canceled) 16. An orally administrable composition comprising a broccoli extract or powder and magnesium or a salt or complex thereof. 17. The orally administrable composition of claim 16, wherein the broccoli extract or powder comprises glucoraphanin in an amount of about 1 to about 75% w/w. 18. The orally admin... | The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof. The invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a ... | 1,600 |
302 | 302 | 14,550,713 | 1,639 | Provided herein, among other things, is a method comprising: (a) obtaining a mixture of multiple sets of oligonucleotides, wherein the oligonucleotides within each set each comprise a terminal indexer sequence can be assembled to produce a synthon; and (b) hybridizing the oligonucleotide mixture to an array, thereby sp... | 1. A method comprising:
(a) obtaining a mixture of multiple sets of oligonucleotides, wherein the oligonucleotides within each set each comprise a terminal indexer sequence and can be assembled to produce a synthon; and (b) hybridizing the oligonucleotide mixture to an array, thereby spatially-separating the different ... | Provided herein, among other things, is a method comprising: (a) obtaining a mixture of multiple sets of oligonucleotides, wherein the oligonucleotides within each set each comprise a terminal indexer sequence can be assembled to produce a synthon; and (b) hybridizing the oligonucleotide mixture to an array, thereby sp... | 1,600 |
303 | 303 | 14,120,309 | 1,618 | Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a l... | 1. A method of delivering a nanoparticle to the brain of a subject comprising administering to the subject a nanoparticle having a nanoparticle core and a targeting agent, wherein said targeting agent includes a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to... | Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a l... | 1,600 |
304 | 304 | 15,758,593 | 1,653 | Provided is a method for preparing a glycoprotein sugar chain including: an isolation step of acting a sugar chain-isolating enzyme on a sample which contains a glycoprotein fixed to a solid phase in a container to obtain an isolated product which contains a sugar chain; and a labeling step of adding a labeling reagent... | 1-22. (canceled) 23. A method for preparing a glycoprotein sugar chain, comprising:
an isolation step of acting a sugar chain-isolating enzyme on a sample which contains a glycoprotein fixed to a solid phase in a container to obtain an isolated product which contains a sugar chain; and a labeling step of adding a label... | Provided is a method for preparing a glycoprotein sugar chain including: an isolation step of acting a sugar chain-isolating enzyme on a sample which contains a glycoprotein fixed to a solid phase in a container to obtain an isolated product which contains a sugar chain; and a labeling step of adding a labeling reagent... | 1,600 |
305 | 305 | 13,320,629 | 1,643 | The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia. | 1. A method for treating cancer cells or tumours that are CD47+, comprising modulating the interaction between human Sirpα and human CD47. 2. The method of claim 1, wherein the interaction between human Sirpα and human CD47 is modulated by administering a therapeutically effective amount of a polypeptide capable of bin... | The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.1. A metho... | 1,600 |
306 | 306 | 14,672,789 | 1,641 | Apparatus is disclosed for identifying at least a first target condition in a human or animal body. The apparatus comprises one or more test portions for identifying a first analyte in a biological sample from the body, the first analyte providing a marker of the first target condition, and a second analyte in the biol... | 1. A pregnancy test device for identifying pregnancy in a human or animal body, the device comprising:
one or more test portions for identifying:
human chorionic gonadotropin (hCG) in the biological sample; and
luteinizing hormone (LH) in the biological sample; and
a processor adapted to:
identify a level of the hCG i... | Apparatus is disclosed for identifying at least a first target condition in a human or animal body. The apparatus comprises one or more test portions for identifying a first analyte in a biological sample from the body, the first analyte providing a marker of the first target condition, and a second analyte in the biol... | 1,600 |
307 | 307 | 14,863,600 | 1,619 | A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin . Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to redu... | 1. A method of improving the barrier function of skin, said method comprising applying to the skin a topical composition comprising an extract of Ampelopsis grossedentata, an extract of Albizia julibrissin and a topical carrier. 2. The method of claim 1, wherein the extracts are polar extracts prepared using polar solv... | A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin . Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to redu... | 1,600 |
308 | 308 | 15,213,444 | 1,625 | The invention relates to compounds of formula (I)
where
R 1 , R 2 , R 3 , R 4 are each independently selected from —(C 1 -C 12 )-alkyl, —(C 3 -C 12 )-cycloalkyl, —(C 3 -C 12 )-heterocycloalkyl, —(C 6 -C 20 )-aryl... | 1. Compound of formula (I)
where
R1, R2, R3, R4 are each independently selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, —(C3-C20)-heteroaryl;
at least one of the R1, R2, R3, R4 radicals is a —(C3-C20)-heteroaryl radical; and
R1, R2, R3, R4, if they are —(C1-C12)... | The invention relates to compounds of formula (I)
where
R 1 , R 2 , R 3 , R 4 are each independently selected from —(C 1 -C 12 )-alkyl, —(C 3 -C 12 )-cycloalkyl, —(C 3 -C 12 )-heterocycloalkyl, —(C 6 -C 20 )-aryl... | 1,600 |
309 | 309 | 13,805,981 | 1,611 | This invention relates to disinfectant compositions comprising a first active ingredient comprising a source of acetyl radicals, and a second active ingredient comprising a source of peroxygen, the composition being soluble in water to provide a solution of peracetic acid. | 1. A disinfectant composition comprising a first active ingredient comprising a source of acetyl radicals, and a second active ingredient comprising a source of peroxygen, the composition being soluble in water to provide a solution of peracetic acid. 2. A disinfectant composition according to claim 1 in tablet form. 3... | This invention relates to disinfectant compositions comprising a first active ingredient comprising a source of acetyl radicals, and a second active ingredient comprising a source of peroxygen, the composition being soluble in water to provide a solution of peracetic acid.1. A disinfectant composition comprising a firs... | 1,600 |
310 | 310 | 12,698,224 | 1,631 | There is provided a computer system for visualizing and editing single molecule fragments and one or more previously-produced single molecule assemblies or “contigs.” The present visualization and editing system allows a user to visualize large data sets resulting from single molecule map assembly operations, and to ra... | 1. A computer system for validating single molecule assemblies, the computer system comprising:
(a) a first database comprising single molecule data, the single molecule data comprising image data derived from optical mapping of a single molecule assembly; (b) a second database comprising biomedical data associated wit... | There is provided a computer system for visualizing and editing single molecule fragments and one or more previously-produced single molecule assemblies or “contigs.” The present visualization and editing system allows a user to visualize large data sets resulting from single molecule map assembly operations, and to ra... | 1,600 |
311 | 311 | 15,052,781 | 1,631 | Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbo... | 1. A method of generating a sequence of codon identifiers corresponding to a sequence of human readable symbols, and assigned according to a coding scheme to convey a non-genetic message in a human reference language, the method comprising:
(i) receiving the sequence of human readable symbols at a memory module; (ii) l... | Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbo... | 1,600 |
312 | 312 | 14,105,489 | 1,627 | The present application relates to personal care compositions including perfumes and sulfur-based perfume raw materials, and methods for making and using the personal care compositions to resist consumer fragrance habituation. | 1. A personal care composition comprising a perfume, the perfume comprising, based on total perfume weight, from about 0.000001% to about 10%, of a perfume raw material comprising a sulfur atom, such that the perfume raw material resists the fragrance habituation of a consumer to the personal care composition. 2. The p... | The present application relates to personal care compositions including perfumes and sulfur-based perfume raw materials, and methods for making and using the personal care compositions to resist consumer fragrance habituation.1. A personal care composition comprising a perfume, the perfume comprising, based on total pe... | 1,600 |
313 | 313 | 14,445,434 | 1,613 | A method of improving the look and feel of skin by using a two-step regimen that includes applying an underlying layer of a skin care composition and applying an overlying layer of a finisher composition on top of the underlying skin care composition layer. The finisher composition is an oil-in-water emulsion comprisin... | 1. A method of improving the look and feel of skin, comprising:
a. applying an underlying layer of a skin care composition to a target portion of skin; and b. applying an overlying layer of a finisher composition on top of the underlying skin care composition layer, wherein the finisher composition is an oil-in-water e... | A method of improving the look and feel of skin by using a two-step regimen that includes applying an underlying layer of a skin care composition and applying an overlying layer of a finisher composition on top of the underlying skin care composition layer. The finisher composition is an oil-in-water emulsion comprisin... | 1,600 |
314 | 314 | 15,322,881 | 1,646 | A method for treating ocular-disorders which, involve angiogenesis or neovascularization as part of their pathologic process. These types of retinal disorders can be categorized as (a) retinal vascular disorders (such as diabetic retinopathy, retinal vein occlusions and retinopathy of prematurity), (b) subretinal neova... | 1. A method for reducing the likelihood or inhibiting the progression of an ocular disorder in a patient in need comprising administering to said patient an effective amount of a hCG/LH antagonist, optionally in combination with an additional bioactive agent effective for ameliorating the effects of said ocular disorde... | A method for treating ocular-disorders which, involve angiogenesis or neovascularization as part of their pathologic process. These types of retinal disorders can be categorized as (a) retinal vascular disorders (such as diabetic retinopathy, retinal vein occlusions and retinopathy of prematurity), (b) subretinal neova... | 1,600 |
315 | 315 | 13,645,871 | 1,628 | A compound of formula (I) is described
and use thereof as fragrance, especially as lily-of-the-valley fragrance and/or as an agent for increasing the substantivity and/or the retention of a fragrance preparation and/or as a fixa... | 1. A compound selected from the group consisting of a compound of formula (Ia)
and a compound of formula (Ib) 2. A mixture, comprising a compound of formula (Ia) and a compound of formula (Ib), as defined in claim 1. 3. A mixture according to claim 2, wherein
the mass ratio of the compound of formula (Ia) to... | A compound of formula (I) is described
and use thereof as fragrance, especially as lily-of-the-valley fragrance and/or as an agent for increasing the substantivity and/or the retention of a fragrance preparation and/or as a fixa... | 1,600 |
316 | 316 | 15,742,512 | 1,618 | The present invention relates to a method of in vivo imaging and in particular to a method for the evaluation of in vivo images of beta amyloid (Aβ) distribution in the brain of a subject suspected of having Alzheimer's disease (AD). The method of the present invention provides more detailed information to the clinicia... | 1. A method for staging beta amyloid (Aβ) pathology in a subject's brain wherein said method comprises:
(i) obtaining an in vivo image of said subject's brain using a Aβ imaging agent;
(ii) determining from said in vivo image the uptake of said Aβ imaging agent in a cortical region of said brain; and,
(iii) determining... | The present invention relates to a method of in vivo imaging and in particular to a method for the evaluation of in vivo images of beta amyloid (Aβ) distribution in the brain of a subject suspected of having Alzheimer's disease (AD). The method of the present invention provides more detailed information to the clinicia... | 1,600 |
317 | 317 | 15,310,195 | 1,623 | A medicament for accelerated wound healing is proposed containing derivatives of the formula (I), in which R 1 stands for hydrogen or methyl. | 1. A drug containing a derivative of the formula (I)
in which R1 denotes hydrogen or methyl, for acceleration of wound healing. 2. The drug according to claim 1, wherein said drug is Sandalore®. 3. The drug according to claim 1, wherein said drug is Brahmanol®. 4. A method for acceleration of wound healing, c... | A medicament for accelerated wound healing is proposed containing derivatives of the formula (I), in which R 1 stands for hydrogen or methyl.1. A drug containing a derivative of the formula (I)
in which R1 denotes hydrogen or methyl, for acceleration of wound healing. 2. The drug according to claim 1, wherei... | 1,600 |
318 | 318 | 14,572,664 | 1,611 | An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice ( Pediculus humanus capitis ). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surf... | 1. A topical formulation comprising
about 0.1% to about 2.0% by weight ivermectin, a solubilizer, about 20% to 30% by weight olive oil, one or more one paraben preservatives, a non-ionic surfactant, and about 30% to 40% by weight water. 2. The topical formulation of claim 1, comprising about 0.5% by weight ivermectin. ... | An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice ( Pediculus humanus capitis ). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surf... | 1,600 |
319 | 319 | 13,688,078 | 1,618 | This disclosure describes example antimicrobial compositions that may be used in combination with IV port cleansing caps, protective caps, or nasal decolonizer devices. According to another implementations, the disclosure describes that the antimicrobial composition may provide an indication that it has come into conta... | 1. A method comprising:
identifying a surface to be decontaminated; applying a medical applicator to the surface, wherein the medical applicator comprises:
a cap device comprising a cylindrical cavity, the cylindrical cavity having a foam insert or a nasal decolonizer device comprising a reservoir; and
an antimicrobial... | This disclosure describes example antimicrobial compositions that may be used in combination with IV port cleansing caps, protective caps, or nasal decolonizer devices. According to another implementations, the disclosure describes that the antimicrobial composition may provide an indication that it has come into conta... | 1,600 |
320 | 320 | 12,956,058 | 1,632 | Devices and methods for treating defects in peripheral nerves are provided. The devices can include acellular arterial tissue matrices that facilitate regrowth of nerve tissue across a gap or defect in a peripheral nerve. | 1. A method for treating a nerve, comprising:
selecting a peripheral nerve having a gap across a portion of its length; and positioning an arterial tissue matrix across the gap, wherein substantially all of the native cells have been removed from the tissue matrix. 2. The method of claim 1, wherein the arterial tissue ... | Devices and methods for treating defects in peripheral nerves are provided. The devices can include acellular arterial tissue matrices that facilitate regrowth of nerve tissue across a gap or defect in a peripheral nerve.1. A method for treating a nerve, comprising:
selecting a peripheral nerve having a gap across a po... | 1,600 |
321 | 321 | 15,891,852 | 1,632 | Compositions and surgical methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 1. A method of surgery for repairing a degenerative cartilage in a patient utilizing an organic active ingredient, the method comprising:
administering a therapeutically effective amount of one or more peptides to the degenerative cartilage, wherein the one or more peptides is selected from the group consisting of: a g... | Compositions and surgical methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.1. A method of surgery for repairing a degenerative cartilage in a patient utilizing an organic active ingredient, the method comprising:
administering a therapeutically effe... | 1,600 |
322 | 322 | 13,120,112 | 1,619 | The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer c... | 1. A pH-dependent controlled release pharmaceutical composition, comprising:
a core comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated by at least one coating layer controlling the release of the pharmaceutical composition, the at least one coating layer ... | The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer c... | 1,600 |
323 | 323 | 14,773,088 | 1,649 | This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders. | 1. A method of increasing viability of a neuronal cell in a subject suffering from a demyelinating disorder, comprising administering to the subject an effective amount of a compound of Formula I:
or a derivative or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are independently hy... | This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.1. A method of increasing viability of a neuronal cell in a subject suffering from a demyelinating disorde... | 1,600 |
324 | 324 | 14,110,549 | 1,619 | Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tis... | 1-53. (canceled) 54. A method of localized delivery of a bioactive agent to a tissue, the method comprising:
positioning in a subject a multilayer thin film medical device comprising:
a first layer comprising a polymer and a pore forming agent;
a bioactive agent; and
a second layer in contact with the bioactive agent;
... | Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tis... | 1,600 |
325 | 325 | 13,132,840 | 1,632 | Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. | 1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:
harvesting stem cells from the patient in need thereof; culturing the harvested stem cells under selective pressure that corresponds to the environment of a damaged intervertebral disc; and implanting the selected stem ... | Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:
harvesting stem cells from the patient in need thereof; culturing the harvested st... | 1,600 |
326 | 326 | 14,238,439 | 1,635 | Disclosed are oligomeric compounds which are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. The hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. | 1.-272. (canceled) 273. A oligomeric compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein the modified oligonucleotide has a modification motif comprising:
a 5′-region consisting of 2-8 linked 5′-region nucleosides, each independently selected from among a modified nucleosid... | Disclosed are oligomeric compounds which are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. The hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.1.-272. (canceled) 273. A oligomeric compound comp... | 1,600 |
327 | 327 | 15,418,017 | 1,617 | The invention relates to a composition, especially a cosmetic composition, including water, at least one film-forming agent, at least one volumizing agent, and an emulsification system comprising (i) about 2% to about 6% of low HLB emulsifier(s) (HLB value less than 8), (ii) about 2% to about 8% of intermediate HLB emu... | 1. A composition comprising water, at least one dispersion of film forming particles in aqueous phase, at least one volumizing agent, and an emulsification system comprising about 2% to about 6% of low HLB emulsifier(s), about 2% to about 8% of intermediate HLB emulsifier(s), and about 1% to about 8% of high HLB emulsi... | The invention relates to a composition, especially a cosmetic composition, including water, at least one film-forming agent, at least one volumizing agent, and an emulsification system comprising (i) about 2% to about 6% of low HLB emulsifier(s) (HLB value less than 8), (ii) about 2% to about 8% of intermediate HLB emu... | 1,600 |
328 | 328 | 14,806,487 | 1,658 | The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least... | 1. A modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof. 2. The modified peptide according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the sugar su... | The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least... | 1,600 |
329 | 329 | 15,157,656 | 1,631 | A hemodialysis patient data acquisition and management system resides on a host computer which receives information from one or more non-invasive, optical blood monitors associated with a hemodialysis system. When a patient is undergoing hemodialysis treatment, a sensor assembly monitors the patient's blood flowing thr... | 1. A system for hemodialysis patient data acquisition and management, comprising:
a hemodialysis system, configured to draw blood from a patient, pass the drawn blood through extracorporeal tubing and through a dialyzer, and return the dialyzed blood through extracorporeal tubing to the patient; a non-invasive blood mo... | A hemodialysis patient data acquisition and management system resides on a host computer which receives information from one or more non-invasive, optical blood monitors associated with a hemodialysis system. When a patient is undergoing hemodialysis treatment, a sensor assembly monitors the patient's blood flowing thr... | 1,600 |
330 | 330 | 14,674,536 | 1,616 | A sunscreen composition including a polymer composition that contains a UV-absorbing polyglycerol having a UV-absorbing chromophore chemically bound thereto, and a cosmetically-acceptable topical carrier that contains at least one percent by weight of the sunscreen composition of a non-UV-absorbing polyglycerol, based ... | 1. A sunscreen composition comprising:
a polymer composition comprising a UV-absorbing polyglycerol comprising a UV-absorbing chromophore chemically bound thereto; and a cosmetically-acceptable topical carrier comprising at least one percent of a non-UV-absorbing polyglycerol, based on the total weight of said sunscree... | A sunscreen composition including a polymer composition that contains a UV-absorbing polyglycerol having a UV-absorbing chromophore chemically bound thereto, and a cosmetically-acceptable topical carrier that contains at least one percent by weight of the sunscreen composition of a non-UV-absorbing polyglycerol, based ... | 1,600 |
331 | 331 | 12,735,595 | 1,635 | The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands. | 1. A cationic siRNA, characterized in that it is a fragment of double-stranded RNA, at the ends of which are grafted oligocations, the number of grafted cationic charges being comparable to or greater than that of the anionic charges borne by the internucleoside phosphates of the RNA strands. 2. The cationic siRNA as c... | The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands.1. A ... | 1,600 |
332 | 332 | 14,913,132 | 1,627 | The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the ... | 1. An indole compound of the following Formula (1) or a pharmaceutically acceptable salt or isomer thereof:
in which
m denotes a number of 1 to 3;
n denotes a number of 0 to 2;
R1 represents hydrogen, C1-C6-alkyl, —(CH2)n—C3-C6-cycloalkyl or —(CH2)n-heterocyclyl, wherein heterocyclyl is a 4- to 8-membered rin... | The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the ... | 1,600 |
333 | 333 | 15,497,414 | 1,625 | Provided herein are compounds and pharmaceutical compositions of formula I
where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds.... | 1: A compound of formula I having a chemical structure of
wherein R1 is
R2 and R3 are independently hydrogen or C1-4 alkyl;
R4 is H or C1-4 alkyl;
R5 is phenyl, aryl, heterocyclyl or aralkyl any of which is substituted with one or more of hydrogen, C1-4 alkyl, alkoxy, aryloxy, oxo, halogen, haloalk... | Provided herein are compounds and pharmaceutical compositions of formula I
where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds.... | 1,600 |
334 | 334 | 12,903,521 | 1,632 | The present disclosure provides methods of generating germ layers from stem cells comprising culturing the stem cells in a culture medium having an osmolality less than 340 mOsm/kg. The present disclosure also includes a method to generate different cell lineages from the germ layers as well as to detect them by immuno... | 1. A method of generating a population of germ layer progenitor cells comprising:
a) dissociating pluripotent stem cells into clusters or single cells; b) culturing the dissociated cells from a) in culture media with an osmolality of 260 to 340 mOsm/kg; and c) dissociating the cells of b) and plating the cells onto coa... | The present disclosure provides methods of generating germ layers from stem cells comprising culturing the stem cells in a culture medium having an osmolality less than 340 mOsm/kg. The present disclosure also includes a method to generate different cell lineages from the germ layers as well as to detect them by immuno... | 1,600 |
335 | 335 | 14,334,462 | 1,634 | A system for fast DNA sequencing by amplification of genetic material within microreactors, denaturing, demulsifying, and then sequencing the material, while retaining it in a PCR/sequencing zone by a magnetic field. One embodiment includes sequencing nucleic acids on a microchip that includes a microchannel flow chann... | 1. A method of sequencing nucleic acids on a microchip, comprising the steps of:
providing a microchannel flow channel in the microchip; isolating the nucleic acids; hybridizing the nucleic acids to magnetic nanoparticles or to magnetic polystyrene-coated beads; forming microreactors in said microchannel flow channel, ... | A system for fast DNA sequencing by amplification of genetic material within microreactors, denaturing, demulsifying, and then sequencing the material, while retaining it in a PCR/sequencing zone by a magnetic field. One embodiment includes sequencing nucleic acids on a microchip that includes a microchannel flow chann... | 1,600 |
336 | 336 | 13,582,372 | 1,657 | The invention relates to the determination of resistances of microorganisms which produce β-lactamases, in particular “extended spectrum β-lactamases” (ESBL). The invention provides a method whereby the microbial resistance can be measured very simply and quickly by means of the catalytic effect of the microbially prod... | 1. Method for the determination of a β-lactam resistance of microbes based on the production of β-lactamases by the microbes, wherein the microbes are brought together with a substrate and the enzymatic breakdown of the substrate by the β-lactamases of the microbes is measured mass spectrometrically by acquiring a mass... | The invention relates to the determination of resistances of microorganisms which produce β-lactamases, in particular “extended spectrum β-lactamases” (ESBL). The invention provides a method whereby the microbial resistance can be measured very simply and quickly by means of the catalytic effect of the microbially prod... | 1,600 |
337 | 337 | 15,067,901 | 1,618 | A method of magnetic resonance imaging a target tissue in a subject includes a step of administering a first Eu 2+ -containing complex to the subject. The first Eu 2+ -containing complex has a reduction potential that is more negative than a reduction potential for a selected compound present in the target tissue. A fi... | 1. A method of magnetic resonance imaging a target tissue in a subject, the method comprising:
a) administering a first Eu2+-containing complex to the subject, the first Eu2+-containing complex having a reduction potential that is more negative than a reduction potential for a selected compound present in the target ti... | A method of magnetic resonance imaging a target tissue in a subject includes a step of administering a first Eu 2+ -containing complex to the subject. The first Eu 2+ -containing complex has a reduction potential that is more negative than a reduction potential for a selected compound present in the target tissue. A fi... | 1,600 |
338 | 338 | 14,310,568 | 1,616 | A composition directed to comprising from about 25% to about 60% a pyrithione or polyvalent metal salt of a pyrithione; from about 0.01 to about 1% of a cationic polymer; from about 0.01% to about 2.0% of an anionic surfactant wherein the cationic polymer has a molecular weight from about 100,000 to about 2,000,000. | 1. A composition comprising:
a) from about 25% to about 60% of a pyrithione or polyvalent metal salt of a pyrithione; b) from about 0.01 to about 1% of a cationic polymer; c) from about 0.01% to about 2.0% of an anionic surfactant; wherein the cationic polymer has a molecular weight from about 100,000 to about 2,000,00... | A composition directed to comprising from about 25% to about 60% a pyrithione or polyvalent metal salt of a pyrithione; from about 0.01 to about 1% of a cationic polymer; from about 0.01% to about 2.0% of an anionic surfactant wherein the cationic polymer has a molecular weight from about 100,000 to about 2,000,000.1. ... | 1,600 |
339 | 339 | 15,234,084 | 1,627 | A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treat... | 1. A method of relieving pain and/or promoting wound healing in a patient due a pilonidal sinus wound, hidradenitis or pressure sore wounds, the method comprising:
applying to the damaged skin area a topical composition, wherein the topical composition consists essentially of metronidazole in a therapeutically effectiv... | A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treat... | 1,600 |
340 | 340 | 15,395,233 | 1,644 | Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluoresc... | 1-18. (canceled) 19. A polynucleotide that encodes the polypeptide comprising:
a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus. 20. A cell comprising the polynucleotide of claim ... | Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluoresc... | 1,600 |
341 | 341 | 14,886,238 | 1,662 | A high protein (up to 40%) tetraploid oat variety is provided that is suitable for large scale oat production using standard farming practices. A tetraploid oat variety includes one or more of lodging resistance, shattering resistance, erect growth habit, and seeds similar to traditional cultivated hexaploid oat, A. s... | 1. A plant of a tetraploid oat variety that is cultivatable using one or more standard farming practices. 2. The plant of claim 1, wherein the standard farming practices include mechanical planting, mechanical harvesting, and/or mechanical milling. 3. The plant of claim 1, wherein the plant is Avena magna. 4. The plant... | A high protein (up to 40%) tetraploid oat variety is provided that is suitable for large scale oat production using standard farming practices. A tetraploid oat variety includes one or more of lodging resistance, shattering resistance, erect growth habit, and seeds similar to traditional cultivated hexaploid oat, A. s... | 1,600 |
342 | 342 | 12,086,453 | 1,612 | A method for preparing a product for treating the skin and mucous membranes comprises the steps of making available a suitable quantity of trichloracetic acid, making available a suitable quantity of hydrogen peroxide, making a first mixture of the trichloracetic acid and the hydrogen peroxide, making available a deter... | 1. A method for preparing a product for treating the skin and mucous membranes, comprising the following steps:
a) to make available a suitable quantity of trichloracetic acid (CCl3COOH or TCA); b) to make available a suitable quantity of hydrogen peroxide (H2O2); c) to make a first mixture of said trichloracetic acid ... | A method for preparing a product for treating the skin and mucous membranes comprises the steps of making available a suitable quantity of trichloracetic acid, making available a suitable quantity of hydrogen peroxide, making a first mixture of the trichloracetic acid and the hydrogen peroxide, making available a deter... | 1,600 |
343 | 343 | 14,353,443 | 1,653 | The invention relates to a process for the conversion of lignocellulose into an organic acid including an alkaline pretreatment step and a fermentation step, wherein liquid phase obtained in the fermentation step is recycled to the alkaline pretreatment step and/or the fermentation step. Organic acid is recovered as it... | 1. A process for the conversion of lignocellulose into an organic acid, the process comprising the following steps:
a) pretreating a feed comprising lignocellulose material with an alkaline agent comprising a divalent cation, wherein the divalent cation is a calcium or magnesium cation, in the presence of water at a pr... | The invention relates to a process for the conversion of lignocellulose into an organic acid including an alkaline pretreatment step and a fermentation step, wherein liquid phase obtained in the fermentation step is recycled to the alkaline pretreatment step and/or the fermentation step. Organic acid is recovered as it... | 1,600 |
344 | 344 | 14,419,010 | 1,631 | The invention relates to the identification of microbes in a sample by calculating the similarities between a mass spectrum of the sample and all reference spectra in a spectral library; it particularly concerns the detection of microbe mixtures. Microbe mixtures are probably present if several microbe species which ar... | 1. Method for the recognition of microbe mixtures in the mass-spectrometric identification of a microbe sample, with compilation of a score list of the reference spectra in a library which are most similar to the sample spectrum, wherein, if two or more microbe species are present in the score list, the relationships b... | The invention relates to the identification of microbes in a sample by calculating the similarities between a mass spectrum of the sample and all reference spectra in a spectral library; it particularly concerns the detection of microbe mixtures. Microbe mixtures are probably present if several microbe species which ar... | 1,600 |
345 | 345 | 11,322,156 | 1,627 | The invention relates to medicine and is directed at developing means and methods for narcological practice and for preventive measures in order to reduce the risk of falling sick with such menacing modem diseases like dependence diseases, in particular alcoholism, narcomania and toximania. Said invention provides for ... | 1. A method for the prevention of beginnings and/or for the prevention of development and/or for reducing the rate of development of pathological processes caused by the use of alcohol-containing beverages and/or substances having an addictive potential, comprising (a) providing a preparation comprising at least one vi... | The invention relates to medicine and is directed at developing means and methods for narcological practice and for preventive measures in order to reduce the risk of falling sick with such menacing modem diseases like dependence diseases, in particular alcoholism, narcomania and toximania. Said invention provides for ... | 1,600 |
346 | 346 | 13,622,263 | 1,645 | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 1.-36. (canceled) 37. A composition for immunizing a subject suffering from or at risk of a condition, the composition comprising:
a replication defective adenovirus vector comprising a deletion in the E2b region and one or more nucleic acids encoding a variant of an antigen associated with said condition or a fragment... | Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.1.-36. (canceled) 37. A composition for immunizing a subject suffering from or at risk of a condition, th... | 1,600 |
347 | 347 | 15,485,026 | 1,627 | A method for treating a subject afflicted with dementia is disclosed. The method comprises administering to the subject a composition comprising an effective amount of a benzoic acid, a salt, an ester, or a derivative thereof, and a pharmaceutically acceptable carrier or vehicle, wherein the subject is not administered... | 1. A method of treating dementia, comprising:
administering to a patient with dementia, excluding a patient with a Clinical Dementia Rating (CDR) score of 0.5, a therapeutically effective amount of benzoic acid, a salt, an ester, or a derivative thereof. 2. The method of claim 1, further comprising administering an ace... | A method for treating a subject afflicted with dementia is disclosed. The method comprises administering to the subject a composition comprising an effective amount of a benzoic acid, a salt, an ester, or a derivative thereof, and a pharmaceutically acceptable carrier or vehicle, wherein the subject is not administered... | 1,600 |
348 | 348 | 14,045,683 | 1,656 | The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, s... | 1. A method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising:
providing a mutated yeast cell, wherein said mutation comprises an inactivation of at least one gene of the (PDH) by-pass, selecte... | The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, s... | 1,600 |
349 | 349 | 15,203,616 | 1,642 | Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy ... | 1. A method for diagnosing a liver pathology in a subject suspected of having the liver pathology comprising:
obtaining biological fluid from the subject; contacting said biological fluid with a fucose-binding lectin and allowing said lectin to bind to a protein in said biological fluid, wherein said protein is selecte... | Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy ... | 1,600 |
350 | 350 | 15,206,623 | 1,619 | A method of inhibiting PAR2 activation of keratinocytes by boosting the PAR2 inhibition ability of a vitamin B3 compound and an N-acyl amino acid compound with a Laminaria Saccharina extract. The method may be used to improve the appearance of hyperpigmented spots on skin. By determining the amount of Laminaria Sacc... | 1. A method of boosting the ability of a vitamin B3 compound and an N-acyl amino acid compound to inhibit PAR2 activation of keratinocytes, comprising:
a. identifying one or more keratinocytes in which inhibition of PAR2 activation is desired; b. applying an effective amount of a vitamin B3 compound and an N-acyl amino... | A method of inhibiting PAR2 activation of keratinocytes by boosting the PAR2 inhibition ability of a vitamin B3 compound and an N-acyl amino acid compound with a Laminaria Saccharina extract. The method may be used to improve the appearance of hyperpigmented spots on skin. By determining the amount of Laminaria Sacc... | 1,600 |
351 | 351 | 15,100,780 | 1,663 | The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigarg... | 1. A method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of:
(a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigargin family; and (b) recovering on... | The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigarg... | 1,600 |
352 | 352 | 14,899,394 | 1,651 | A cell culture article, including: a substrate comprising a polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid having a degree of esterification from 1 to 40 mol %, or salts thereof; and an adhesion polymer on the surface of the polygalacturonic acid compound. A ... | 1. A cell culture article, comprising:
a substrate comprising a polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid having a degree of esterification from 1 to 40 mol %, or salts thereof; and an adhesion polymer on the surface of the polygalacturonic acid compound... | A cell culture article, including: a substrate comprising a polygalacturonic acid compound selected from at least one of: pectic acid; partially esterified pectic acid having a degree of esterification from 1 to 40 mol %, or salts thereof; and an adhesion polymer on the surface of the polygalacturonic acid compound. A ... | 1,600 |
353 | 353 | 14,834,914 | 1,663 | The present invention relates to methods of producing lipids. In particular, the present invention relates to methods of increasing the level of one or more non-polar lipids and/or the total non-polar lipid content in a transgenic organism or part thereof. In one particular embodiment, the present invention relates to ... | 1. A method of producing extracted lipid, the method comprising the steps of:
i) obtaining a transgenic non-human organism or part thereof comprising one or more exogenous polynucleotides, wherein the transgenic non-human organism or part thereof has an increased level of one or more non-polar lipids when compared to a... | The present invention relates to methods of producing lipids. In particular, the present invention relates to methods of increasing the level of one or more non-polar lipids and/or the total non-polar lipid content in a transgenic organism or part thereof. In one particular embodiment, the present invention relates to ... | 1,600 |
354 | 354 | 13,683,444 | 1,613 | Disclosed are systems for use in administering inhaled nitric oxide gas as a therapeutic treatment, where the systems reduce the risk of inducing an increase in pulmonary capillary wedge pressure leading to pulmonary edema in neonatal patients who have hypoxic respiratory failure and are candidates for inhaled nitric o... | 1. A system for use in administering inhaled nitric oxide gas, which system reduces the risk of inducing an increase in pulmonary capillary wedge pressure (PCWP) leading to pulmonary edema in neonatal patients who have hypoxic respiratory failure and are candidates for inhaled nitric oxide treatment, the system compris... | Disclosed are systems for use in administering inhaled nitric oxide gas as a therapeutic treatment, where the systems reduce the risk of inducing an increase in pulmonary capillary wedge pressure leading to pulmonary edema in neonatal patients who have hypoxic respiratory failure and are candidates for inhaled nitric o... | 1,600 |
355 | 355 | 15,519,559 | 1,627 | Disclosed herein are methods and formulation for enhancing oral availability of CPT-11 during cancer therapy while at the same time, reducing its gastrointestinal (GI) toxicity, thus the methods and formulations as disclosed herein may augment the efficacy of cancer therapy. | 1. A method of reducing CPT-11 induced gastrointestinal (GI) toxicity in a subject underwent a CPT-11 treatment, comprising,
administering 1-50 mg/Kg of silychristin to the subject so as to ameliorate or alleviate symptoms of CPT-11 induced GI toxicity. 2. The method of claim 1, wherein the silychristin is administered... | Disclosed herein are methods and formulation for enhancing oral availability of CPT-11 during cancer therapy while at the same time, reducing its gastrointestinal (GI) toxicity, thus the methods and formulations as disclosed herein may augment the efficacy of cancer therapy.1. A method of reducing CPT-11 induced gastro... | 1,600 |
356 | 356 | 14,525,903 | 1,649 | Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 1-15. (canceled) 16. Isolated neural precursor cells, prepared by a process comprising the steps of:
(a) expanding mesenchymal stem cells isolated from a human subject, (b) culturing a portion of the expanded mesenchymal stem cells obtained in step (a) in a neural progenitor basal medium (NPBM) supplemented with epider... | Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.1... | 1,600 |
357 | 357 | 15,609,253 | 1,611 | The present invention relates to compositions and methods for the prevention and treatment of skin disorders and for the rejuvenation of the skin. In particular, the application describes topical compositions and methods of treatments comprising the combined use of one or more cannabinoids and one or more hydroxy acids... | 1. A topical composition for the rejuvenation or treatment of skin in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen comprising therapeutically effective amounts of at least one cannabinoid and at least one hydroxy acid in a topically acceptable carrier, wherein the c... | The present invention relates to compositions and methods for the prevention and treatment of skin disorders and for the rejuvenation of the skin. In particular, the application describes topical compositions and methods of treatments comprising the combined use of one or more cannabinoids and one or more hydroxy acids... | 1,600 |
358 | 358 | 15,159,726 | 1,616 | The present disclosure provides a method of adapting salmonidae fish for growth on soy protein-containing diets. The method comprises, within an effective period of time after the fish hatch, administering to the fish a fish feed composition. The fish feed composition comprises soy protein and an effective amount of an... | 1. A method of adapting fish to be resistant to inflammatory enteritis induced by soy protein, the method comprising:
a) providing to a fish population in water a feed composition containing at least about 1% (by weight) soy protein and an effective amount of an antioxidant after members of said fish population begin t... | The present disclosure provides a method of adapting salmonidae fish for growth on soy protein-containing diets. The method comprises, within an effective period of time after the fish hatch, administering to the fish a fish feed composition. The fish feed composition comprises soy protein and an effective amount of an... | 1,600 |
359 | 359 | 15,430,815 | 1,652 | The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein... | 1. A pharmaceutical composition comprising
a) human lysosomal acid lipase (hLAL) protein or peptide, or a protein or peptide having at least 85% sequence homology to human lysosomal acid lipase; and b) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is an isotonic sterile injectab... | The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein... | 1,600 |
360 | 360 | 14,480,449 | 1,631 | A method of characterising a sample from spectrometric data using calculation of spectral distance values is disclosed, for use in the field of mass spectrometry. Molecular formula assignment of peaks in mass spectral data is difficult and time-consuming, and the invention provides a computer implemented method of find... | 1. A computer implemented method of characterizing a sample by identifying a most likely elemental composition of a measured peak of interest in a spectrum obtained from that sample, comprising the steps of:
(a) identifying, for the peak of interest in the spectrum of the sample, a plurality of elemental compositions h... | A method of characterising a sample from spectrometric data using calculation of spectral distance values is disclosed, for use in the field of mass spectrometry. Molecular formula assignment of peaks in mass spectral data is difficult and time-consuming, and the invention provides a computer implemented method of find... | 1,600 |
361 | 361 | 14,776,323 | 1,613 | Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related meth... | 1. A method of enhancing the adhesive properties of an adhesive composition, wherein the adhesive composition comprises an adhesive component, an absorbent, and a vehicle, the method comprising:
providing a crystallization inhibitor; incorporating the crystallization inhibitor in the adhesive composition, whereby the a... | Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related meth... | 1,600 |
362 | 362 | 15,533,710 | 1,612 | Provided herein is an oral care composition comprising taurine or a salt thereof in an amount of from 0.001 weight % to 0.008 weight % by total weight of the composition, and an orally acceptable carrier. The composition is effective in accelerating HSP 27 production in damaged tissues of the oral cavity and enhances r... | 1. An oral care composition comprising taurine or a salt thereof in an amount of from 0.001 weight % to 0.05 weight %, e.g., 0.001 weight % to 0.008 weight % by total weight of the composition, and an orally acceptable carrier. 2. The composition of claim 1, wherein the taurine or salt thereof is present in the composi... | Provided herein is an oral care composition comprising taurine or a salt thereof in an amount of from 0.001 weight % to 0.008 weight % by total weight of the composition, and an orally acceptable carrier. The composition is effective in accelerating HSP 27 production in damaged tissues of the oral cavity and enhances r... | 1,600 |
363 | 363 | 11,908,237 | 1,612 | Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided. | 1. A method of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject, the method comprising:
contacting at least a portion of the interior surface of an opening leading to the internal cavity with an antimicrobial composition; and subsequently at... | Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided.1. A method of delaying the onset of an infection or p... | 1,600 |
364 | 364 | 14,966,843 | 1,649 | CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (C SF) of a patient who is suffering from a dementia or neuroinflammatory disease or is su... | 1-13. (canceled) 14. A method for assisting in the detection and diagnosis of dementias selected from the group consisting of Alzheimer's dementia (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and various forms of vascular dementia (VAD), said method comprising:
determining the level of procalcit... | CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (C SF) of a patient who is suffering from a dementia or neuroinflammatory disease or is su... | 1,600 |
365 | 365 | 12,439,692 | 1,616 | The invention provides aqueous pesticidal concentrates comprising at least one colloidal solid, a dispersed emulsion phase comprising at least one substantially water-insoluble pesticidally active ingredient, which is either itself an oily liquid comprising the oil phase, is a solid but is dissolved in an oily liquid p... | 1. A liquid pesticidal emulsion composition comprising
(a) an aqueous continuous phase; (b) at least one colloidal solid; and (c) a dispersed oil emulsion phase comprising
(i) at least one substantially water-insoluble pesticidally active ingredient, which is either itself an oily liquid comprising the oil phase, is a ... | The invention provides aqueous pesticidal concentrates comprising at least one colloidal solid, a dispersed emulsion phase comprising at least one substantially water-insoluble pesticidally active ingredient, which is either itself an oily liquid comprising the oil phase, is a solid but is dissolved in an oily liquid p... | 1,600 |
366 | 366 | 13,656,573 | 1,613 | Vitamin E compositions, methods of making such compositions and therapeutic uses of vitamin E compositions are disclosed. Compositions of matter comprising a tocotrienol making up at least 15 dry basis weight percent of the composition of matter and a constituent selected from a triglyceride and a triglyceride ester, w... | 1. A composition of matter comprising:
a. a tocotrienol based composition making up at least 15 dry basis weight percent of the composition of matter; and b. a constituent selected from a triglyceride and a triglyceride ester; c. wherein upon mixing of the composition of matter with water the tocotrienol based composit... | Vitamin E compositions, methods of making such compositions and therapeutic uses of vitamin E compositions are disclosed. Compositions of matter comprising a tocotrienol making up at least 15 dry basis weight percent of the composition of matter and a constituent selected from a triglyceride and a triglyceride ester, w... | 1,600 |
367 | 367 | 15,411,083 | 1,645 | The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune r... | 1. A composition comprising as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as another component one or more antigens. 2. The composition of claim 1, wherein the slurry matrix comprises a peptide... | The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune r... | 1,600 |
368 | 368 | 13,997,344 | 1,613 | Described herein are oral fluid compositions comprising one or more structuring agents, and methods of making and using the same. | 1. A fluid composition comprising:
one or more structuring agents selected from the group consisting of: a gum-type colloidal polymer; a cellulosic polymer; an acrylate polymer; and a clay or fine particulate; and an orally acceptable aqueous carrier;
wherein the composition is a mouthwash or mouthrinse, and
wherein t... | Described herein are oral fluid compositions comprising one or more structuring agents, and methods of making and using the same.1. A fluid composition comprising:
one or more structuring agents selected from the group consisting of: a gum-type colloidal polymer; a cellulosic polymer; an acrylate polymer; and a clay or... | 1,600 |
369 | 369 | 15,528,604 | 1,612 | The present disclosure is directed to a method for reducing bacteria in a precipitated calcium carbonate (CaCO 3 ) slurry, the method including: adding water to calcium oxide (CaO) to form Ca(OH) 2 ; treating the Ca(OH) 2 with CO 2 gas to form a slurry including precipitated CaCO 3 ; neutralizing the slurry; and expo... | 1. A method for reducing bacteria in a precipitated calcium carbonate (CaCO3) slurry, the method comprising:
adding water to calcium oxide (CaO) to form Ca(OH)2: treating the Ca(OH)2 with CO2 gas to form a slurry comprising precipitated CaCO3; neutralizing the slurry; and exposing the slurry that was neutralized to ozo... | The present disclosure is directed to a method for reducing bacteria in a precipitated calcium carbonate (CaCO 3 ) slurry, the method including: adding water to calcium oxide (CaO) to form Ca(OH) 2 ; treating the Ca(OH) 2 with CO 2 gas to form a slurry including precipitated CaCO 3 ; neutralizing the slurry; and expo... | 1,600 |
370 | 370 | 15,288,121 | 1,651 | Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful products, such as fuels. For example, systems can use feedstock materials, such as cellulosic and/or lignocellulosic materials, to proceed ethanol and/or butanol, e.g., by fermentation. | 1-18. (canceled) 19. A mixture comprising:
an aqueous solution comprising a low molecular weight sugar, a fermenting microorganism, and a lignocellulosic material that has been irradiated with at least 10 Mrad of electron beam radiation, the lignocellulosic material having a BET surface area greater than 0.1 m2/g and a... | Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful products, such as fuels. For example, systems can use feedstock materials, such as cellulosic and/or lignocellulosic materials, to proceed ethanol and/or butanol, e.g., by fermentation.1-18. (canceled) 19. A mixtur... | 1,600 |
371 | 371 | 13,392,596 | 1,653 | The present invention relates to a production method for cryopreserved acellular dermal matrix and to cryopreserved acellular dermal matrix produced thereby, and more specifically it relates to a method in which a cryopreservation agent is made by adding sucrose to basic components consisting of glycerol and a basic so... | 1. A method for preparing a cryopreserved acellular dermal matrix comprising:
i) removing epidermis of allograft skin; ii) removing cells in dermis; iii) mixing glycerol, and a basic solution selected from a buffer solution and an animal cell culture medium; iv) dissolving sucrose in the solution to a final concentrati... | The present invention relates to a production method for cryopreserved acellular dermal matrix and to cryopreserved acellular dermal matrix produced thereby, and more specifically it relates to a method in which a cryopreservation agent is made by adding sucrose to basic components consisting of glycerol and a basic so... | 1,600 |
372 | 372 | 12,922,432 | 1,663 | A technique by which the production of plant biomass can be significantly increased is provided. A protein phosphatase 2C gene having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order is over-expressed. | 1. A plant, in which a gene encoding protein phosphatase 2C having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 in such order from the N-terminal side is over-expressed. 2. The plant according to claim 1, wherein the gene encoding protein phosphatase 2C is at least one gene selecte... | A technique by which the production of plant biomass can be significantly increased is provided. A protein phosphatase 2C gene having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order is over-expressed.1. A plant, in which a gene encoding protein p... | 1,600 |
373 | 373 | 14,057,243 | 1,644 | The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The ant... | 1. A method for enhancing the binding of the Fc region of an IgG antibody or IgG antibodies to an FcγRIII receptor, the method comprising:
modifying the glycosylation of the IgG antibody or antibodies so that the binding of the Fc region of the antibody or antibodies to the FcγRIII receptor is enhanced,
wherein the gly... | The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The ant... | 1,600 |
374 | 374 | 13,825,601 | 1,654 | The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoro-propan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide;... | 1. A compound selected from the following compounds and pharmaceutically acceptable salts, solvates, and hydrates thereof:
3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol... | The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoro-propan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide;... | 1,600 |
375 | 375 | 14,424,198 | 1,613 | Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride is described. Compositions incorporating such materials, as well as methods of preparing such materials are also described. | 1. A composition comprising chlorhexidine gluconate solubilized in a monoacylglyceride, wherein the monoacylglyceride is hydrophobic monoacylglyceride having a hydrophilic-lipophilic balance of no greater than 10 as determined using the HLB Method. 2. The composition of claim 1, comprising at least 5% by weight chlorhe... | Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride is described. Compositions incorporating such materials, as well as methods of preparing such materials are also described.1. A composition comprising chlorhexidine gluconate solubilized in a monoacylglyceride, wherein the monoacylglyceride is hydro... | 1,600 |
376 | 376 | 15,785,769 | 1,627 | The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also appli... | 1. A method for treating a patient suffering from a thermoregulatory dysfunction comprising administering to said patient a compound selected from paroxetine, a pharmaceutically acceptable salt thereof, a hydrate or solvate of either, in any polymorphic form, and mixtures thereof; said compound being in an amount, base... | The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also appli... | 1,600 |
377 | 377 | 15,108,098 | 1,612 | The present invention provides an oral care composition comprising a carboxylic acid of the formula (I) wherein: R 1 is H, or is a substituted or unsubstituted alkyl group; and R 2 is H, OH, or NH 2 ; for use in: (a) selectively promoting, in an oral cavity: growth, metabolic activity or colonization of bacteria that... | 1. An oral care composition comprising a carboxylic acid of the formula:
wherein:
R1 is H, or is a substituted or unsubstituted alkyl group; and
R2 is H, OH, or NH2;
for use in:
(a) selectively promoting, in an oral cavity: growth, metabolic activity or colonization of bacteria that have beneficial effects ... | The present invention provides an oral care composition comprising a carboxylic acid of the formula (I) wherein: R 1 is H, or is a substituted or unsubstituted alkyl group; and R 2 is H, OH, or NH 2 ; for use in: (a) selectively promoting, in an oral cavity: growth, metabolic activity or colonization of bacteria that... | 1,600 |
378 | 378 | 13,381,202 | 1,662 | The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means to increase expression level of a bHLH subgroup 1b gene expression or activity, wherein a desired phenotype such as increased heat tolerance relative to a wild ty... | 1. A method of producing a transgenic plant, comprising transforming a plant, a plant tissue culture, or a plant cell with a vector comprising a nucleic acid construct that increases the expression or activity of a bHLH subgroup 1b gene to obtain a plant, tissue culture or a plant cell with increased bHLH expression or... | The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means to increase expression level of a bHLH subgroup 1b gene expression or activity, wherein a desired phenotype such as increased heat tolerance relative to a wild ty... | 1,600 |
379 | 379 | 14,127,606 | 1,655 | The present invention generally relates to the prevention or treatment of disorders related to oxidative stress. For example, the present invention provides a composition for use in the prevention or treatment of oxidative stress related disorders under post-operative conditions. One embodiment of the present invention... | 1. A method for the treatment, prevention or alleviation of oxidative stress and/or related disorders induced by ischemia-reperfusion comprising administering a composition comprising DHA and EPA as active ingredients to a patient in need of same. 2. Method in accordance with claim wherein the composition comprises EPA... | The present invention generally relates to the prevention or treatment of disorders related to oxidative stress. For example, the present invention provides a composition for use in the prevention or treatment of oxidative stress related disorders under post-operative conditions. One embodiment of the present invention... | 1,600 |
380 | 380 | 15,034,698 | 1,617 | The present invention relates to a composition comprising a polymeric elastomeric phase and an odoriferous active compound. In particular the present invention relates to a composition comprising a polymeric elastomeric phase and an odoriferous active compound and releasing said odoriferous active compound over a given... | 1. A composition comprising
an elastomeric phase of macromolecular sequences having a flexible nature with a glass transition temperature of less than 20° C. and at least one active ingredient as odoriferous active compound which is an organic molecule having a molecular weight of at least 16 g/mol and an odour thresho... | The present invention relates to a composition comprising a polymeric elastomeric phase and an odoriferous active compound. In particular the present invention relates to a composition comprising a polymeric elastomeric phase and an odoriferous active compound and releasing said odoriferous active compound over a given... | 1,600 |
381 | 381 | 14,512,071 | 1,611 | There is provided herein an organofunctional polysiloxanes comprising hydroxyl polyester groups made by reaction of epoxy functional polyorganosiloxanes and oligmeric polyesters based on polyhydroxy carboxylic acids.
There is also provided methods for making the organofunctional polysiloxanes and agricultural, co... | 1. A polysiloxane compound having the general formula (I):
[MaDbD*cTdQe]f (I)
wherein M=R1R2R3SiO1/2; D=R4R5SiO2/2; D*=R6R7SiO2/2; T=R8SiO3/2; Q=SiO4/2; with a=1-10 b=0-1000 c=0-1000 d=0-1 e=0-1 f=1-10 wherein R1, R2, R3, R4, R5, R6 and R8 are each independently selected from the group consisting of monovalent hydro... | There is provided herein an organofunctional polysiloxanes comprising hydroxyl polyester groups made by reaction of epoxy functional polyorganosiloxanes and oligmeric polyesters based on polyhydroxy carboxylic acids.
There is also provided methods for making the organofunctional polysiloxanes and agricultural, co... | 1,600 |
382 | 382 | 14,774,807 | 1,653 | The invention relates to enzyme containing water-soluble films, and their use in detergents. | 1. A method of making an enzyme containing water-soluble film, the method comprising use of a liquid enzyme formulation with an OD440 (10 mm path length) <0.15 per % AEP. 2. A method of making an enzyme containing water-soluble film, the method comprising use of a liquid enzyme formulation with an odor threshold of les... | The invention relates to enzyme containing water-soluble films, and their use in detergents.1. A method of making an enzyme containing water-soluble film, the method comprising use of a liquid enzyme formulation with an OD440 (10 mm path length) <0.15 per % AEP. 2. A method of making an enzyme containing water-soluble ... | 1,600 |
383 | 383 | 13,483,674 | 1,617 | The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular extracellular matrices. In addition, the present disclosure provides systems and methods for using such products. | 1. A method for producing a tissue product, comprising:
selecting an adipose tissue; mechanically processing the adipose tissue to reduce the tissue size; treating the mechanically processed tissue to remove substantially all cellular material from the tissue; suspending the tissue in a solution; and cross-linking the ... | The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular extracellular matrices. In addition, the present disclosure provides systems and methods for using such products.1. A method for producing a tis... | 1,600 |
384 | 384 | 15,084,441 | 1,627 | The poly(ε-caprolactone)-ethoxylated fatty acid copolymers are block copolymers including ε-caprolactone units and ethoxylated fatty alcohol units, the block copolymer having the structural formula:
where n and m are integers gr... | 1. A poly(ε-caprolactone)-ethoxylated fatty alcohol copolymer, comprising a block copolymer having at least one ε-caprolactone unit and ethoxylated fatty alcohol units, the block copolymer having the structural formula:
where n and m are integers greater than 0 and R is an alkyl group, and
wherein the poly(ε-... | The poly(ε-caprolactone)-ethoxylated fatty acid copolymers are block copolymers including ε-caprolactone units and ethoxylated fatty alcohol units, the block copolymer having the structural formula:
where n and m are integers gr... | 1,600 |
385 | 385 | 13,043,021 | 1,611 | There is provided a device comprising a body structure having one or more surfaces wherein at least one of the surfaces comprises a pH sensitive layer comprising a linear polymer, wherein the water solubility of the linear polymer increases from a first water solubility to a second water solubility at a pH trigger. A m... | 1. A device comprising a body structure having one or more surfaces wherein at least one of the surfaces comprises a pH sensitive layer comprising a linear polymer, wherein the water solubility of the linear polymer increases from a first water solubility to a second water solubility at a pH trigger and the linear poly... | There is provided a device comprising a body structure having one or more surfaces wherein at least one of the surfaces comprises a pH sensitive layer comprising a linear polymer, wherein the water solubility of the linear polymer increases from a first water solubility to a second water solubility at a pH trigger. A m... | 1,600 |
386 | 386 | 15,330,732 | 1,661 | A new cherry tree variety suitable for use as rootstock. | 1. A new and distinct variety of cherry tree substantially as described and illustrated herein. | A new cherry tree variety suitable for use as rootstock.1. A new and distinct variety of cherry tree substantially as described and illustrated herein. | 1,600 |
387 | 387 | 15,330,734 | 1,661 | A new cherry tree variety suitable for use as rootstock. | 1. A new and distinct variety of cherry tree substantially as described and illustrated herein. | A new cherry tree variety suitable for use as rootstock.1. A new and distinct variety of cherry tree substantially as described and illustrated herein. | 1,600 |
388 | 388 | 14,356,650 | 1,628 | A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable strong base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH val... | 1. A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH value r... | A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable strong base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH val... | 1,600 |
389 | 389 | 15,096,228 | 1,655 | A method of treating hypertension can include administering to a patient in need thereof a therapeutically effective amount of an extract of Matricaria chamomilla L. The extract can be administered orally to the patient in an amount of about 100 mg/kg to about 200 mg/kg. | 1. A method of treating hypertension, comprising administering orally to a patient in need thereof a therapeutically effective amount of an extract of Matricaria chamomilla only, wherein the Matricaria chamomilla is from the Al-Alnofood desert region of Saudi Arabia, further wherein the therapeutically effective amount... | A method of treating hypertension can include administering to a patient in need thereof a therapeutically effective amount of an extract of Matricaria chamomilla L. The extract can be administered orally to the patient in an amount of about 100 mg/kg to about 200 mg/kg.1. A method of treating hypertension, comprisin... | 1,600 |
390 | 390 | 11,432,226 | 1,611 | A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, su... | 1-117. (canceled) 118. The pharmaceutical composition of claim 140, wherein the paste is difficult to crush, dissolve, heat, evaporate, or extract. 119-128. (canceled) 129. A transdermal patch comprising the composition of claim 118. 130. A capsule comprising the composition of claim 118. 131. The capsule of claim 130,... | A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, su... | 1,600 |
391 | 391 | 14,648,715 | 1,699 | Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of analgesic oils comprising (a) clove oil and/or eugenol, (b) a cooling agent, and (c) camphor, in an orally acceptable gel base, the gel base comprising an anionic polymer and a basic amino acid, and the analgesic gel providing control... | 1. An orally acceptable topical analgesic gel comprising:
a mixture of analgesic oils comprising (a) clove oil and/or eugenol, (b) a cooling agent, and (c) camphor; and an orally acceptable gel base comprising:
an anionic polymer and a basic amino acid;
wherein the gel base provides controlled release of the mixture ... | Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of analgesic oils comprising (a) clove oil and/or eugenol, (b) a cooling agent, and (c) camphor, in an orally acceptable gel base, the gel base comprising an anionic polymer and a basic amino acid, and the analgesic gel providing control... | 1,600 |
392 | 392 | 10,605,669 | 1,653 | The claimed subject matter comprises a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant... | 1. A method of making a collection device for cells comprising of:
providing a tube having an open end and a closed end; preloading compounds including: an anticoagulant agent, and a fixative agent into said tube, said fixative agent selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dim... | The claimed subject matter comprises a device to collect and preserve cells comprising of: (1) a collection container comprised of a tube having an open end and a closed end, a closure in the open end of the tube, a vacuum drawn to a predetermined level inside the container; and (2) compounds including an anticoagulant... | 1,600 |
393 | 393 | 16,122,360 | 1,616 | Abuse-resistant therapeutic pharmaceutical formulations include a cationic drug and at least one anionic polymer. Particular arrangements of the cationic drug and the at least one anionic polymer prevent the cationic drug from being extracted from the formulations in solvents and conditions commonly used by drug abuser... | 1. An abuse-resistant therapeutic pharmaceutical formulation comprising: a cationic drug and at least one anionic polymer; wherein (i) the cationic drug is physically blended with but not ionically bound to the at least one anionic polymer, or (ii) more than 40% of the cationic drug is ionically bound (complexed) to th... | Abuse-resistant therapeutic pharmaceutical formulations include a cationic drug and at least one anionic polymer. Particular arrangements of the cationic drug and the at least one anionic polymer prevent the cationic drug from being extracted from the formulations in solvents and conditions commonly used by drug abuser... | 1,600 |
394 | 394 | 15,340,538 | 1,699 | The present application provides for a compound of Formula IV,
or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of ... | 1-41. (canceled) 42. An in vivo metabolic product of Compound P: 43. The metabolic product of claim 42 which is substantially isolated. 44. A method of preparing the in vivo metabolic product of claim 42 comprising contacting Compound P with a mammal for a period of time sufficient to yield the in vivo metabolic produc... | The present application provides for a compound of Formula IV,
or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of ... | 1,600 |
395 | 395 | 13,905,015 | 1,618 | Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments. | 1. A composition comprising particles which would result from forming said particle from a mixture of
a) an amphiphilic stabilizer, b) a conjugate of the formula
(active−linker)n−hydrophobic moiety (1)
wherein n is an integer of 1-100; and wherein “active” refers to at least a first therapeutic agent; “linker” is a... | Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.1. A composition comprising particles which would result from forming said particle from a mixture of
a) an amp... | 1,600 |
396 | 396 | 15,527,103 | 1,617 | A pharmaceutical composition for aerosol administration and method of preventing or treating a pulmonary disease or condition in a subject with a SphK1 inhibitor are provided. | 1. A method of preventing or treating a pulmonary disease or condition in a subject comprising administering to a subject in need of treatment an effective amount of a SphK1 inhibitor to prevent or treat the subject's pulmonary disease or condition, wherein the SphK1 inhibitor
(a) exhibits at least a 20-fold greater se... | A pharmaceutical composition for aerosol administration and method of preventing or treating a pulmonary disease or condition in a subject with a SphK1 inhibitor are provided.1. A method of preventing or treating a pulmonary disease or condition in a subject comprising administering to a subject in need of treatment an... | 1,600 |
397 | 397 | 14,651,356 | 1,611 | Disclosed are extruded pesticide granules that when mixed with water form a near micro-emulsion that is highly stable. The extruded pesticide granules include at least one pesticide active ingredient, a non-ionic surfactant, and a carrier, which is desirably urea powder or urea pearl. Processes for making the extruded ... | 1. An extruded pesticide granular composition comprising urea, a non-ionic surfactant, a pesticide active ingredient, and water. 2. The extruded composition of claim 1 wherein the urea is in the form of urea pearls. 3. The extruded composition of claim 1 wherein the non-ionic surfactant is a block copolymer having a mo... | Disclosed are extruded pesticide granules that when mixed with water form a near micro-emulsion that is highly stable. The extruded pesticide granules include at least one pesticide active ingredient, a non-ionic surfactant, and a carrier, which is desirably urea powder or urea pearl. Processes for making the extruded ... | 1,600 |
398 | 398 | 13,992,953 | 1,653 | Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and t... | 1-5. (canceled) 6. A method of identifying multipotent mesenchymal stem cells capable of high proliferation comprising the steps of
collecting mesenchymal stem cells; measuring the expression of NG2; and selecting the mesenchymal stem cells with high expression of NG2. 7. The method identifying multipotent mesenchymal ... | Variations in the differentiation and lineage potential of stem cells, including mesenchymal stem cells, currently limit their therapeutic use. The ability to identify, isolate, and specifically amplify stem cell populations with desired differentiation potential would contribute the use of stem cells in research and t... | 1,600 |
399 | 399 | 15,697,723 | 1,626 | The present invention provides a new process for the preparation of a substituted imidazothiazolone compound. The process of the present invention uses a fluoride-free Lewis acid which is cheap and friendly to environment, and provide high selectivity and yield. | 1. A process for the preparation of a substituted imidazothiazolone compound of formula (I), or a stereoisomer thereof, or a stereoisomeric mixture thereof, which comprises:
reacting a compound of formula (II), or a stereoisomer thereof, or a stereoisomeric mixture thereof, with a nucleophile in the presence of a fluor... | The present invention provides a new process for the preparation of a substituted imidazothiazolone compound. The process of the present invention uses a fluoride-free Lewis acid which is cheap and friendly to environment, and provide high selectivity and yield.1. A process for the preparation of a substituted imidazot... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.